Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors
申请人:Ting Pauline C.
公开号:US20090170861A1
公开(公告)日:2009-07-02
In its many embodiments, the present invention provides -substituted pyridazinone compounds as glucan synthase inhibitors, methods of preparing such compounds, pharmaceutical including one or more of such compounds, methods of preparing pharmaceutical formulations including one or more such compounds or one or more such compounds along with other antifungal agents, and methods of treatment, prevention, inhibition, or amelioration of one or more fungal infections associated with glucan synthase using such compounds or pharmaceutical compositions.
Pyridazinone derivatives useful as glucan synthase inhibitors
申请人:Merck Sharp & Dohme Corp.
公开号:EP2586778A2
公开(公告)日:2013-05-01
In its many embodiments, the present invention provides -substituted pyridazinone compounds as glucan synthase inhibitors, methods of preparing such compounds, pharmaceutical including one or more of such compounds, methods of preparing pharmaceutical formulations including one or more such compounds or one or more such compounds along with other antifungal agents, and methods of treatment, prevention, inhibition, or amelioration of one or more fungal infections associated with glucan synthase using such compounds or pharmaceutical compositions.
[EN] ANTITUMOR COMPOUND TARGETING IDH2 MUTATION AND METHOD OF USE THEREOF<br/>[FR] COMPOSÉ ANTITUMORAL CIBLANT LA MUTATION DE IDH2 ET SON PROCÉDÉ D'UTILISATION<br/>[ZH] 靶向IDH2突变的抗肿瘤化合物及其使用方法
ANTITUMOR COMPOUND TARGETING IDH2 MUTATION AND METHOD OF USE THEREOF
申请人:CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
公开号:US20180222853A1
公开(公告)日:2018-08-09
The present application relates to compounds represented by general formula (I), general formula (II) or general formula (III), and pharmaceutically acceptable salts or hydrates thereof, preparation methods thereof, and pharmaceutical compositions thereof. The compounds represented by general formula (I), general formula (II) or general formula (III) have inhibitory activities against isocitrate dehydrogenase 2 (IDH2), thereby being capable of treating IDH2 mutation-induced cancers.